## **European Respiratory Society Annual Congress 2013**

**Abstract Number: 3625** 

**Publication Number: P2550** 

Abstract Group: 4.2. Sleep and Control of Breathing

Keyword 1: Apnoea / Hypopnea Keyword 2: Sleep disorders Keyword 3: Sleep studies

**Title:** Predictors of nocturnal hypertension in obstructive sleep apnea patients with metabolic syndrome

Dr. Radostina 22160 Cherneva cherneva\_radost@yahoo.com MD ¹, Prof. Ognian 22161 Georgiev ogeorgiev@hotmail.com MD ¹, Prof. Daniela 22162 Petrova ssn@multicom.bg MD ¹, Dr. Tsanko 22163 Mondeshki tz.m@abv.bg MD ¹, Dr. Radoslav 29206 Biluykov za\_rado@abv.bg MD ¹ and Prof. Emil 29220 Manov d-r\_emil\_manov@abv.bg MD ¹. ¹ Internal Medicine, University Hospital, Sofia, Bulgaria .

Body: Background: Patients with obstructive sleep apnea (OSA) are more likely to have nocturnal blood pressure (NBP) abnormalities than. Thus the study of clinical factors affecting NBP is of practical value. Aim: To define the role of glucometabolic, sleep study parameters and biomarkers (resistin, free fatty acids - FFA and isoprostanes) in determining OSA patients with nocturnal hypertension. Materials and methods: 87 patients with newly diagnosed OSA and metabolic syndrome (MetS) participated in the study. OSA was verified by a polysomnography. MetS was diagnosed according to IDF, 2005. All patients were treated for hypertension. An ambulatory 24-hour BP monitoring was done to discern (NH) - nocturnal hypertensives (NBP >120/70mmHg) from (NN) - nocturnal normotensives. Anthropological, glucometabolic and sleep study characteristics were also assessed. Resistin and FFA plasma levels were measured. Urinary isoprostanes were measured determined by high resolution mass spectrometry. Results: According to ABPM 78% of the patients had controlled hypertension; 22% had refractory hypertension;57% were with NH. Refractory hypertension was encountered only in NH patients. NH did not differ significantly from NN regarding the anthromopetric measurements. From sleep study parameters only the duration of sleep with SaO2<90% was s longer in NH – 61,29±31,97 vs 37,61±32,64, p-0.002 in NN. Glucometabolic markers could not differentiate NH from NN except for HbA1C 6,4±1,02 vs 5,9 ±0,66, p=0,024. Resistin, FFA and isoprostanes were similar. Conclusions: HbA1c and the average duration of sleep with SatO2<90% could be of clinical value in the detection of nocturnal hypertension in patients with OSA and MetS.